Cabio Biotech (Wuhan) Co., Ltd.

Shanghai Stock Exchange 688089.SS

Cabio Biotech (Wuhan) Co., Ltd. Inventory for the year ending December 31, 2023: USD 15.86 M

Cabio Biotech (Wuhan) Co., Ltd. Inventory is USD 15.86 M for the year ending December 31, 2023, a 34.28% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.

Cabio Biotech (Wuhan) Co., Ltd. Inventory for the year ending December 31, 2022 was USD 11.81 M, a 0.24% change year over year.
Cabio Biotech (Wuhan) Co., Ltd. Inventory for the year ending December 31, 2021 was USD 11.78 M, a 17.44% change year over year.
Cabio Biotech (Wuhan) Co., Ltd. Inventory for the year ending December 31, 2020 was USD 10.03 M, a 6.07% change year over year.
Cabio Biotech (Wuhan) Co., Ltd. Inventory for the year ending December 31, 2019 was USD 9.46 M, a -3.69% change year over year.

Key data

Date	Inventory	Goodwill	Total Assets	Current Liabilities

Shanghai Stock Exchange: 688089.SS

Cabio Biotech (Wuhan) Co., Ltd.

CEO	Mr. Dewei Yi
IPO Date	Dec. 19, 2019
Location	China
Headquarters	No. 999 high-tech Avenue
Employees	508
Sector	Consumers Staples
Industries Pet Food Baby & Childcare Consumer Packaged Goods Cosmetics Dairy & Milk Food & Beverages Personal Care Pharmaceuticals

Description

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.

Key trends

Past 5 years